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Abstract: Radiation therapy (RT) is essential in treating women with early stage breast can-
cer. Early stage node-negative breast cancer (ESNNBC) offers a good prognosis; hence, late 
effects of breast RT becomes increasingly important. Recent literature suggests a potential for 
an increase in cardiac and pulmonary events after RT. However, these studies have not taken 
into account the impact of newer and current RT techniques that are now available. Hence, this 
review aimed to evaluate the clinical evidence for each technique and determine the optimal 
radiation technique for ESNNBC treatment. Currently, six RT techniques are consistently used 
and studied: 1) prone positioning, 2) proton beam RT, 3) intensity-modulated RT, 4) breath-
hold, 5) partial breast irradiation, and 6) intraoperative RT. These techniques show dosimetric 
promise. However, limited data on late cardiac and pulmonary events exist due to challenges 
in long-term follow-up. Moving forward, future studies are needed to validate the efficacy and 
clinical outcomes of these current techniques.
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Introduction
An early stage node-negative breast cancer (ESNNBC) offers a good prognosis.1 
Improved surgical techniques, systemic therapy options, and radiation therapy (RT) 
have resulted in significant improvement in long-term cause-specific survival.2,3
Increasing use of RT has resulted in significant increase in long-term survival,2,3 
translating to more women at risk of developing long-term treatment-related toxicities. 
Hence, it is contradictory that the benefits of improved survival, due to the successful 
delivery of RT for ESNNBC, are negated by RT-induced toxicities.
Dosimetry planning for whole breast external beam radiotherapy (WBEBRT) 
typically involves a pair of tangential fields to homogenously treat the entire breast 
while avoiding adjacent vital organs, like the lungs, heart, and left anterior descend-
ing artery (LAD).4
Cardiac toxicity studies demonstrate increased mortality and morbidity from 
heart disease,5–8 especially left-sided WBEBRT patients, 10–15 years after receiving 
irradiation compared to right-sided WBEBRT patients. Recent imaging studies dem-
onstrate consistent occurrence of perfusion defects, microvascular disease, stenosis, 
and atherosclerosis where the heart and coronary arteries are included in the radiation 
field and validate the need to reduce cardiac dose.6,7,9
Lung toxicity studies have demonstrated increased risk of secondary lung cancers 
and mortality for radiation-induced lung cancer post WBEBRT.5 Grantzau and Over-
gaard found that ≥5 years after breast cancer diagnosis, RT was significantly associ-
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ated with an increased risk of radiation-induced lung cancer 
relative risk (RR) of 1.39 (95% CI 1.28–1.51).10
Radiation pneumonitis (RP) arises from irradiation of the 
adjacent ipsilateral lung in breast cancer. It has been reported 
to be related to 1) the amount of lung irradiated within the 
tangential fields, 2) use of supraclavicular field, 3) prior 
exposure to chemotherapy, 4) high-dose chemotherapy, and 
5) concurrent tamoxifen medication and smoking habits.11
Current literature suggests new advanced radiation tech-
niques vis-a-vis delivering and quantifying radiation doses 
to the organs at risk (OAR).12 Such techniques include 1) 
maneuvers to achieve maximum separation of the heart from 
the chest wall (ie, synchronizing RT with the patients’ respira-
tory cycle or prone positioning),13–15 2) designing and utilizing 
cardiac blocks to minimize radiation damage to the heart 
while avoiding over shielding,16 3) utilizing advanced tech-
nologies for RT delivery (ie, intensity-modulated radiation 
therapy [IMRT] or proton beam radiation therapy [PBT]),17,18 
and (4) moving away from whole breast volume to partial 
breast volume treatment (accelerated partial breast irradia-
tion [APBI] or intraoperative radiation therapy [IORT]).19,20
This review aimed to evaluate the evidence for each tech-
nique by 1) identifying the different breast RT techniques for 
ESNNBC, 2) collate the dosimetric outcomes for each breast 
RT technique, and 3) identify the best dosimetric technique.
Methods
Eligible articles include articles about 1) breast cancer RT; 
2) RT-associated toxicities, and 3) published in an English 
language peer-reviewed journal. A systematic search using 
MEDLINE/PubMed and MeSH headings was used to identify 
articles addressing RT techniques. The headings were breast 
cancer, radiation therapy, intensity modulated, prone, partial 
breast, breath-hold (BH), gating, intraoperative, side effects, 
heart, cardiac, lung, and pulmonary.
Articles were excluded if they provided pilot data, 
descriptions of a study design, articles on non-breast cancer 
data, post-mastectomy radiation, lymph node irradiation, 
exclusive evaluation of patients with pectus excavatum, 
bilateral breast irradiation, articles not having heart, LAD, 
and/or lung dosimetric data or non-English language articles.
Articles were reviewed specifically for data from patients 
whose left breast was treated. For dosimetric studies, manda-
tory information included the sample size, techniques used, 
and outcomes. For clinical studies, mandatory information 
included sample size reviewed, RT techniques utilized, whether 
there was a comparison arm, and clinical outcomes (recur-
rence, toxicities, and pulmonary and/or cardiac outcomes).
Given heterogeneity among studies, OAR dosimetric 
parameters were evaluated through three different mecha-
nisms. For lung, these mechanisms are 1) anatomic data 
(ie, volume of lung within irradiated field) and 2) lung dose 
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mechanisms are 1) anatomic data (ie, volume of heart within 




). For LAD, 
1) anatomic data (ie, volume of LAD within irradiated field) 





All searches were completed by June 10, 2017.
Results
Six consistently utilized and studied RT techniques were 
found: 1) prone positioning, 2) PBT, 3) IMRT, 4) BH, 5) 
partial breast irradiation (PBI), and 6) IORT.
Table 1 summarizes the mechanism of each RT technique. 
Table 2 presents the data supporting each technique and the 
key dosimetric findings.
Prone technique
The prone position is a technique where the patient lies on 
a platform with a modifiable aperture through which the 
ipsilateral breast hangs away from the thorax by gravity.21
Lung exposure when lying prone
Literature demonstrates a significant decrease in lung dose 
in the prone position although the left lung volume was 
essentially greater in the prone position.22–26 The breast sits 
Table 1 RT techniques
RT technique Mechanism of technique
Prone positioning Breast falls away from the chest wall thereby increasing the distance of the OARs to the RT beam
Proton beam therapy Unlike the properties of photons, protons allow for a steep dose fall off
intensity-modulated RT Utilizing dose planning algorithms and computerizing each individual leaf position of the multileaf 
collimator to shape the radiation field away from the OARs
Breath-hold Utilizing respiratory inspiration to achieve maximum separation from heart to chest wall
Partial breast irradiation Smaller target volume theoretically decreases OAR dose
intraoperative RT Smaller target volume and sometimes utilizing lower energies to reduce OAR dose
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early stage breast cancer techniques
anterior to the lung when the patient is lying prone. This 
subjects it to the compressive force from the weight of the 
breast. Lying prone prevents this compression, leading to 
better expansion of the lung.27 Hence, the decrease in lung 
dose could be attributed to an increase in the lung volume 
when lying prone. All prone treatment techniques showed 
similar lung dose metrics.
This correlates to decreased lung exposure and possibly 
reduces the risk of radiation-induced lung toxicities. While 
conventional WBERT in the supine position has been shown 
to increase the risk of ipsilateral lung carcinoma with a RR 
of 0.11,28 lying prone could reduce this RR.
Cardiac and LAD exposure when lying prone
With the breast parenchyma falling away from the chest 
wall, this allows the radiation beam edge to be potentially 
placed further away from the heart. This increases the heart 
to chest wall distance and theoretically allows for cardiac 
dose reduction.20,29
NYU trial studied both the supine and prone positions and 
found that 85% of the patients with left breast target lesions 
demonstrated a reduction of in-field heart volume by a mean 
of 11 cc.30 A recent similar trial, consisting of 53 patients with 
left breast cancer also demonstrated similar results where 
87% had a 12 cc mean reduction of in-field heart volume.22 
However, the reduction of in-field heart volume due to the 
prone technique is an inconsistent finding as a comparatively 
small percentage of patients still benefit from the supine 
position compared to the prone position.22,30,31
Kirby et al found an increase in heart dose in eight of 30 
patients receiving whole breast irradiation, with a median 
increase in LAD
mean
 of 9.5 Gy.24 Mulliez et al analyzed supine 
vs prone plans for 18 patients.32 The results demonstrated 
no significant improvement in heart sparing with the prone 
position. Würschmidt et al suggested that cardiac and LAD 
exposure might inadvertently increase due to the anterior 
movement of the heart when lying prone for WBEBRT.33 
There was no difference in the mean heart dose for left WBE-
BRT in the prone (4.16 Gy, 95% CI 3.5–4.9 Gy) and supine 
positions (4.01 Gy; 95% CI 3.4–4.6 Gy; P=0.7). However, 
the LAD received a significantly higher mean dose and no 
improvement in the maximum dose in the prone position. 
For the left breast prone WBEBRT, the LAD received a 
significantly higher average mean dose (33.5 Gy; 95% CI 
29.5–37.4 Gy) compared to left supine WBEBRT (25.6 
Gy; 95% CI 21.4–29.7 Gy; P=0.0051). The average mean 
maximum dose was comparable (P=0.766) between supine 
WBEBRT (43.2 Gy; 95% CI 39.14–47.19 Gy) and prone 
WBEBRT (43.9 Gy; 95% CI 40.73–47 Gy).
Hence, cardiac and coronary artery benef its for 
prone position remains controversial with conflicting 
results.22,29,30,33–35 This could be due to varying contouring 
and treatment techniques among the different institutions.
Concerns regarding the prone technique
Concerns regarding decreased reproducibility of the prone 
position and poor set up from patient discomfort may lead 
to greater potential for increased dose to normal tissues.20,36 
However, Jozsef et al demonstrated that reproducibility of 
the prone position is improved with cone beam CT.37 This is 
at the expense of additional irradiation.38
While early studies postulate poorer cosmetic outcomes 
with the prone technique from risk of erythema, recent 
research have proven comparable or better outcomes com-
pared to the supine technique.23,39,40
Stegman et al conducted the largest long-term study with 
a cohort of 245 patients and a median follow-up of 4.9 years.41 
The prone position resulted in similar long-term disease con-
trol with a favorable toxicity profile compared with standard 
supine tangents. However, it can only be postulated that the 
anatomic advantage of prone positioning may contribute to 
improving the therapeutic ratio of post-lumpectomy radiation 
by improving dose homogeneity and minimizing incidental 
cardiac and lung dose. Long-term follow-up studies evaluat-
ing cardiac and pulmonary outcomes are needed.
Current scenario
Although the evidence for lung sparing is clear, the value of 
cardiac and LAD sparing remains equivocal. Subset analyses 
suggest large-breasted patient generally benefit more from 
the prone position compared to small-breasted patients.40,41
PBT
The potential of PBT lies in its unique physical dose-deposi-
tion properties that allow maximum dose deposition within 
the tumor and rapid dose fall off beyond the Bragg peak. 
This potentially reduces adjacent OARs and subsequently 
toxicities incurred.42–45
Lung, heart, and LAD exposure when utilizing PBT
Dosimetric studies demonstrate dose reduction to the 
OARs.42,43,45 Lin et al demonstrated significant reductions to 
high and low doses to the lung, heart, and LAD where lung 
V
20 Gy
 (photon vs proton: 12.5% vs 0%, P<0.0167), lung 
V
5 Gy
 (photon vs proton: 25.2% vs 4.7%, P<0.0167), lung 
D
mean
 (photon vs proton: 27.3 vs 0.88 Gy, P<0.0167), heart 
V
20 Gy
 (photon vs proton: 0.7% vs 0%, P<0.0167), heart V
5 
Gy
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early stage breast cancer techniques
(photon vs proton: 1.6 vs 0.011 Gy, P<0.0167), LAD D
min
 
(photon vs proton: 1.1 vs 0 Gy), LAD D
max
 (photon vs pro-
ton: 31.8 vs 0.71 Gy, P<0.0167), and LAD D
0.2 cc
 (photon vs 
proton: 10 vs 0.052 Gy, P<0.0167). This could be attributed 
to the physical properties of PBT.
Concerns regarding PBT
Although the merits of PBT lie in its potential to reduce 
radiation-induced morbidities, a prevalent concern underly-
ing the widespread adoption of PBT is its significant cost. 
Proponents for the adoption of breast PBT argue that two 
emerging issues may increase the cost-effectiveness for breast 
PBT. First, as technology rapidly advances and efficiency 
in delivery improves, costs will become more manageable. 
Second, the cost of PBT can be further reduced with the 
adoption of hypofractionated regime.
Current scenario
The advantageous dose distribution and excellent OAR spar-
ing that can be achieved coupled with growing experience 
with PBT makes PBT an attractive option. However, data on 
PBT for breast remains sparse and costs remain significantly 
high. Given limited data and uncertainty in estimating the 
cost–benefits, judicious adoption of PBT is recommended.
iMRT
IMRT is the utility of multileaf collimator (MLC) technology 
to shape and create non-uniform intensity of radiation beams 
as it transverse through the patient’s body.46,47 By varying the 
speeds at which the MLC leaves travel or the shape of the 
beam, the radiation beam is effectively shaped to vary the 
dose distribution to the target volume.47
In recent decades, IMRT has emerged as a revolutionary 
concept that irradiates the tumor more precisely while rela-
tively sparing dose to adjacent OARs. The main advantage 
of IMRT is that it allows dose painting.46
Lung, heart, and LAD exposure with iMRT
OARs dose reductions with IMRT are contradictory. For 
example, Schubert et al demonstrated significant reductions 
in lung V
20 Gy
 (three-dimensional conformal radiotherapy 
[3D CRT] vs IMRT: 14.8% vs 11.8%, P<0.001), lung V
5 Gy
 
(3D CRT vs IMRT: 28.1% vs 24.1%, P<0.001), and lung 
D
mean
 (3D CRT vs IMRT: 8.1 vs 6.6 Gy, P<0.001).48 How-
ever Haciislamoglu et al demonstrated instead a significant 
increase in lung V
20 Gy
 (3D CRT vs IMRT: 12.99% vs 16.64%, 
P=0.005), lung V
5 Gy
 (3D CRT vs IMRT: 19.8% vs 79.92%, 
P<0.001), and lung D
mean
 (3D CRT vs IMRT: 7.66 vs 12.18 
Gy; P<0.001).49 Conflicting results have also been demon-
strated for both the heart and the LAD.
More than 50% of the articles demonstrated a reduction 
in high doses and an increase in low doses to the OARs. This 
increase in low dose could be attributed to two factors: 1) the 
number of monitor units increases which results in increase 
in total body radiation dose and 2) IMRT utilizes more fields 
resulting in greater volume of normal tissues exposed to low 
radiation doses.50,51 Theoretically, an increase in low dose 
exposure leads to increased rates of radiation-induced second-
ary malignancies.49 Compared to 3D CRT, IMRT can poten-
tially increase the incidence of solid secondary cancers due 
to a combination of changed dose distribution and increase 
in monitor units. As radiation-induced carcinogenesis is due 
to the stochastic effect of normal tissue radiation exposure, 
it is imperative that strategies to decrease OAR dose without 
compromising adequate dose coverage are implemented.
Concerns regarding iMRT
Of concern is the conundrum posed by involuntary tumor and 
patient movement. As in all IMRT cases, the planning target 
volume (PTV) drawn must encompass all known diseases. 
This means that all possible movements by both the tumor and 
the patient should be accounted for. An inappropriate margin 
will result in underdosing of the tumor and/or overdosing of 
the surrounding OAR. Hence, extra caution should be taken 
to limit patient movement with an appropriate reproducible 
patient immobilization.46
Another conundrum is the existence of conflicting data 
regarding the dosimetric superiority of IMRT over 3D CRT. 
Compared to prone and breathing techniques, the dosimet-
ric benefits of IMRT proved inconsistent in reducing lung, 
heart, and LAD doses and its associated NTCPs. Although 
literature suggests that IMRT is not routinely advantageous, 
IMRT can prove useful for patients with atypical anatomy 
such as severe pectus excavatum.52
Current scenario
IMRT represents an often-used technique in a clinical setting 
with conflicting data with respect to OAR dose reduction. 
IMRT can also be utilized with breathing techniques, prone 
technique, and PBI.
BH
Respiratory maneuvers, primarily utilized for cardiac dose 
reduction, have been picking up over the past decades.53–55 
Respiratory maneuvers such as inspiration pulls the heart 
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ity.53–55 This increases the heart to chest wall distance. As 
radiation-induced heart toxicities correlates to the in-field 
heart volume within the radiation fields, respiratory maneu-
vers that reduces in-field heart volume shows promise in 
reducing radiation dose to the heart while allowing adequate 
dose to the breast. Later studies affirmed that deep inspiration 
breath-hold (DIBH) represents the optimum point of heart 
displacement.56 With the development of more sustainable 
and reproducible methods, multiple studies were conducted 
comparing free breathing (FB) vs DIBH.
Lung exposure with BH
Conflicting results regarding lung dose reduction with DIBH 
exists with multiple studies demonstrating an increase in lung 
dose with BH. Remouchamps et al demonstrated a significant 
increase in V
20 Gy
 (DIBH vs FB: 20.4% vs 15.2%, P<0.00007) 
with DIBH.56 However, recent studies have also demonstrated 
comparable or nonsignificant increases in lung doses with 
DIBH.57,58 There are two possible reasons why DIBH results 
in the increase in lung dose. First, during DIBH, the lungs 
expand and hence increase in volume. Furthermore, with 
the displacement of the heart away from the chest wall, this 
increases the absolute lung volume within the radiation fields. 
Hence, the significant increase of in-field lung volume cor-
relates to an increase in lung doses. Both Walston et al and 
Mulliez et al demonstrated an increase in lung volume (DIBH 
vs FB: 2,059.39 cc vs 1,181.34 cc, P<0.05 and DIBH vs FB: 
2,090 cc vs 1,235 cc, P<0.001) with DIBH, respectively.57,59 
Second, the maturation of technology has allowed MLCs to 
be employed for customized shielding of normal lung tissue.60 
Hence, although the expansion in lung volume with DIBH 
is inevitable, the correlated significant increase in lung dose 
can be mitigated with the use of MLCs.
Cardiac and LAD exposure with BH
The reduction of in-field heart volume of the heart has 
allowed for a significant DVH reduction, for the heart and 
LAD, with DIBH.
Nissen and Appelt demonstrated a 91% reduction in V
40 Gy
 
(DIBH vs FB: 3.4% to 0.3%, P<0.0001) and a 48% reduction 
in D
mean
 (DIBH vs FB: 5.2 vs 2.7 Gy, P<0.0001) for left-sided 
breast plans.61 This improvement in cardiac dose reduction 
was replicated in a prospective trial conducted by Eldredge-
Hindy et al.62 Significant reductions in heart DVHs such as 
D
mean
 (DIBH vs FB: 0.9 vs 2.7 Gy, P<0.0001), D
max
 (DIBH 
vs FB: 27.9 vs 50.4 Gy, P<0.0001), V
25 Gy
 (DIBH vs FB: 0% 
vs 2.7%, P<0.0001), and V
5 Gy
 (DIBH vs FB: 3% vs 11.1%, 
P<0.0001) were established.62 These results confirm earlier 
cardiac imaging findings demonstrating left ventricular dose 
reduction with DIBH.63–65
The LAD descends along the caudal aspect of the heart 
and is situated in the vicinity of the radiation fields even in BH 
plans. Hence with BH, greater significant reductions to the LAD 
DVHs can be expected. However, greater significant reductions 
to the LAD DVHs can be expected. Mast et al, utilizing a DIBH 
device known as active breathing coordinator (ABC) to perform 
DIBH, demonstrated significant reductions in the LAD DVHs 
such as D
mean
 (ABC vs FB: 9.6 vs 18.6 Gy, P<0.01), D
max
 (ABC 
vs FB: 25.2 vs 35.5 Gy, P<0.01), V
20 Gy
 (ABC vs FB: 17.8% 
vs 42.5%, P<0.01), and V
5 Gy
 (ABC vs FB: 39.4% vs 62.6%, 
P<0.01) with ABC.66 When used in combination with IMRT, 
further reduction in dose was achieved, D
mean
 (ABC vs FB: 
6.7 vs 14.9 Gy, P<0.01), D
max
 (ABC vs FB: 18.8 vs 31.4 Gy, 
P<0.01), V
20 Gy
 (ABC vs FB: 30.3% vs 54.9%, P<0.01), and V
5 
Gy
 (ABC vs FB: 9.7% vs 32.8%, P<0.01). Further reduction was 
demonstrated with IMRT due to a rotation in collimator angle 
which allowed the MLCs to better shield the heart.
BH versus respiratory gating
Two techniques frequently used for breathing cycle manage-
ment are DIBH and respiratory gating.
DIBH can be device assisted, that is, by using ABC or per-
formed voluntarily. A Phase III randomized trial by Bartlett 
et al sought to determine whether voluntary DIBH (vDIBH) 
and ABC result in a discrepancy in normal tissue sparing, 
set up reproducibility and feasibility of delivery.67 In terms 
of normal tissue dose, Bartlett et al found no statistical sig-
nificance in techniques (all P Nonsignificant). Furthermore, 
positional reproducibility and feasibility of delivery were 
also comparable.67
Respiratory gating tracks the respiratory cycles of the 
patient with thoraco-abdominal sensors to trigger radiation 
delivery based on the respiratory phase.68,69 Giraud et al 
evaluated 233 patients and found comparable and consistent 
reduction in heart DVHs.63
Currently, only limited data are available to determine 
the superiority of one breathing technique over another. 
However, the wealth of literature with respect to BH has 
affirmed its efficacy and feasibility in treatment delivery and 
dose reduction to OARs.
A reduction in doses to the OARs correlates to reduction 
in associated radiation-induced OAR toxicities and mortality. 
Korreman et al evaluated the radiobiological implications of 
dosimetric benefits offered with breathing techniques and 
found significant potential.70 Corresponding pneumonitis 
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early stage breast cancer techniques
FB to 2.6% (range: 0.1%–40.1%) with respiratory gating 
and to 4.3% (range: 0.1%–59%) with DIBH. Likewise, 
cardiac mortality probability dropped from 4.8% (range: 
0.1%–23.4%) with FB to 0.5% (range: 0.1%–2.6%) with 
respiratory gating and to 0.1% (range: 0%–3.0%) with DIBH.
Current scenario
BH is undoubtedly one of the most well-studied RT tech-
niques. It can be offered to all patients except patients unable 
to sustain BH or who have poor respiratory function. BH can 
also be used in combination with IMRT.
PBi
PBI is an alternative RT technique that utilizes hypofraction-
ation regimes for selected patients with early stage breast 
cancer. Patient selection is based on a review of clinical and 
pathological factors.4 As only the lumpectomy cavity and a 
margin around it is irradiated, patient selection is the foremost 
factor. This includes assessing presurgical and surgical tumor 
staging to exclude patients at a greater risk of locoregional 
recurrence.71 Hence, with a reduced irradiated volume, it can 
be expected that OARs doses decrease.
Increased fraction size results in increased radiobiologi-
cal equivalent dose to the tumor. However, this is also at the 
expense of late responding fraction-sensitive OARs, such 
as the lungs and heart, receiving incidental radiation at an 
increased dose per fraction too. Hence, a concern regarding a 
hypofractionation regime associated with PBI is the potential 
to increase the risk of lung and heart toxicities due to the low 
α/β of these tissues. The clinical aftermath of receiving higher 
dose per fraction of incidental radiation to these OARs is as 
yet unknown. Current data show that toxicities associated 
with hypofractionation in breast RT have not been correlated 
with increased OAR-related toxicities.72,73
Cardiac and pulmonary exposure with different 
types of PBi
APBI is a form of PBI which can be delivered via interstitial 
devices, applicators, or with external beam.20
The case for APBI lies in that a rare 3%–4% of cases 
report ipsilateral breast recurrences in areas away from the 
tumor bed.74 Based on this evidence, WBEBRT may consti-
tute overtreatment as it incorporates the entire breast (inclu-
sive of the surgical cavity), overlying skin, lower axilla, and 
portions of the heart, lung, and LAD in the treatment fields. 
Even with modern WBEBRT, unavoidable OAR toxicities 
are still introduced where APBI can effectively spare more 
of these OARs. Thus, the theoretical advantage of APBI is 
its reduced dose to normal tissues as it can be expected that 
with a reduced target volume, adjacent OARs such as lungs, 
heart, and LAD will receive less radiation.
Recent long-term studies have attested the clinical 
efficacy of APBI with excellent local control, toxicities, 
and cosmesis that are comparable or reduced compared to 
WBEBRT.75–77
With interstitial APBI, multiple catheters are inserted 
and loaded around the lumpectomy cavity.75 Utilizing high 
dose rate (HDR) brachytherapy, the target volume receives 
a high dose away from the chest wall. Applicator-based 
APBI similarly employs HDR brachytherapy while limiting 
the dose to the chest wall and adjacent OARs too.78 With 
external beam APBI (EB-APBI), target volume margins 
are further enlarged to account for respiratory motions and 
treatment setup uncertainties not typically associated with 
brachytherapy. Multiple noncoplanar fields are optimally 
arranged to limit dose to the OARs.79
Multi-catheter interstitial brachytherapy has the 
 longest follow-up of any APBI technique to date. Modern 
 image-guided techniques have demonstrated reduced OAR 
doses.80,81 Multiplane interstitial APBI plans were evaluated 
for 49 patients. The mean heart dose was found to be 21% 
of the prescribed dose and a mean V
5
 of 12.8 cc for left-
sided breast cancer patients.81 These findings are consistent 
with Lettmaier’s et al study that compared interstitial APBI 
with standard WBEBRT.82 Lettmaier et al demonstrated that 
interstitial APBI was consistent in reducing both high and 
low doses to the OARs; 1) heart D
0.1 cc
 (APBI vs WBEBRT: 
12.59 vs 45.60 Gy, P<0.01), heart D
50 cc
 (APBI vs WBEBRT: 
5.60 vs 18.17 Gy, P<0.01); 2) lung D
0.1 cc
 (APBI vs WBEBRT: 
19.61 vs 51.99 Gy, P<0.01), lung D
50 cc
 (APBI vs WBEBRT: 
8.19 vs 43.38 Gy, P<0.01).82
In recent years, applicator-based brachytherapy has been 
gaining traction. Stewart et al performed a dosimetric analy-
sis comparing balloon-based APBI to WBEBRT and found 
significant reduction in OAR doses too: 1) heart D
max
 (APBI 
vs WBEBRT: 16.6 vs 44.1 Gy, P<0.05), heart V
20 Gy
 (APBI 
vs WBEBRT: 0.1% vs 3.7%, P<0.05); 2) lung D
max
 (APBI 
vs WBEBRT: 31.0 vs 51.6 Gy, P=0.06), lung V
20 Gy
 (APBI vs 
WBEBRT: 1.3% vs 10.0%, P<0.05).83 With the introduction of 
multi-lumen applicators, doses can be better sculpted around the 
target volume to allow further reductions from the OARs.78,84
With EB-APBI, the reduction in OAR doses was sig-
nificantly dependent on the distance from the lumpectomy 
region. For example, Kron et al found that when lumpectomy 
regions are >4 cm away from the heart, the corresponding 
V
5 Gy
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Multiple studies have affirmed that techniques such as 
IMRT, BH, PBT, and prone technique, utilized in WBEBRT 
can be incorporated with APBI to achieve greater OAR 
dose reduction. Wu et al compared IMRT-APBI and IMRT-
WBEBRT and found significant reductions in lung and heart 
DVHs. Lung D
mean
 was reduced by a factor of 2 (IMRT-APBI 
vs IMRT-WBEBRT: 3.17 vs 6.62 Gy, P<0.05) and lung V
20 
Gy
 was reduced by a factor of 6 (IMRT-APBI vs IMRT-WBE-
BRT: 1.97 vs 11.77 Gy, P<0.05).86 Likewise, heart D
mean
 was 
reduced by a factor of 4 (IMRT-APBI vs IMRT-WBEBRT: 0.8 
vs 3.17 Gy, P<0.05) and heart V
20 Gy
 was reduced by a factor 
of 96 (IMRT-APBI vs IMRT-WBEBRT: 0.03 vs 2.88 Gy, 
P<0.05). Moran et al conducted a Phase I/II study evaluating 
the dosimetric impact of APBI with BH.87 With BH, lung D
max
 
(FB-APBI vs BH-APBI: 38.1 vs 35.5 Gy, P>0.001) and D
mean
 
(FB-APBI vs BH-APBI: 2.9 vs 1.7 Gy, P>0.001) was further 
reduced. Likewise, heart D
max
 (FB-APBI vs BH-APBI: 8.2 
vs 4.8 Gy, P>0.001) and D
mean
 (FB-APBI vs BH-APBI: 0.5 
vs 0.4 Gy, P>0.001) was further reduced. Galland-Girodet 
et al conducted a prospective study to compare the impact of 
photons vs proton on APBI OAR dosimetry.88 With proton, 
lung D
max
 (photon-APBI vs proton-APBI: 28.9 vs 20.4 Gy, 
P<0.0001) and Dmean (photon-APBI vs proton-APBI: 2.2 
vs 0.5 Gy, P<0.0001) were further significantly reduced. With 
proton, heart D
max
 (photon-APBI vs proton-APBI: 7.7 vs 3.8 
Gy, P<0.0001) and D
mean
 (photon-APBI vs proton-APBI: 0.9 
vs 0.0 Gy, P<0.0001) was further significantly reduced. EB-
APBI can also be delivered in the prone position. Prospec-
tive trials have demonstrated that EB-APBI is compliant to 
dosimetric requirements.89,90 However, Formenti et al found 
that prone EB-APBI resulted in an increase in cardiac dose 
in 19 of 30 plans compared to a decrease in cardiac dose in 
seven of 30 plans.89
In essence, EB-APBI allows for excellent lung and 
heart dose reduction. However, recent interim cosmetic and 
toxicities results of EB-APBI from the Canadian RAPID 
trial have demonstrated that current prescribed fractionation 
regime for EB-APBI approaches the steep aspect of the 
toxicity curve and cautions against adopting it as standard 
practice.91
Current scenario
APBI is an effective alternative to WBEBRT in the manage-
ment of carefully selected patients with early stage breast 
cancer or ductal carcinoma in situ based on recently published 
consensus guidelines.77 As EB-APBI approaches the steep 
aspect of toxicity curve, we do not advocate the adoption of 
EB-APBI as standard practice.
iORT
IORT represents an alternative to postoperative irradiation 
as it delivers radiation at the time of surgery as a single frac-
tion in most cases. IORT is increasingly offered as definitive 
RT following breast conserving surgery. Currently, data on 
IORT remains far more limited than APBI.92–96 IORT can be 
delivered via electrons utilizing lead shielding to reduce dose 
beyond chest wall.95–98 Aziz et al compared the dosimetric 
gains of utilizing IORT compared to APBI and WBEBRT 
and demonstrated a reduction of D
mean
 from 3.4 to 0.13 and 
0.03 Gy with WBEBRT, APBI, and IORT, respectively.99 
Lung D
max
 was likewise reduced from 53.0 to 7.4 and 1.8 Gy 
with WBEBRT, APBI, and IORT, respectively. Similar find-
ings were also demonstrated for heart dose where heart D
mean
 
was reduced from 1.00 to 0.06 and 0.01 Gy with WBEBRT, 
APBI, and IORT, respectively. Although dosimetric gains 
achieved with IORT are certainly promising, IORT is not 
without its controversy.
Two large randomized trials were undertaken to com-
pare the efficacy of IORT in early stage breast cancer with 
 WBEBRT. The targeted intraoperative radiotherapy (TAR-
GIT) trial found that one-fifth of the IORT cohort needed 
WBEBRT supplementation and was further associated with 
an inferior local control at 5 years (3.3% vs 1.3%, P=0.04).95 
Similarly, the intraoperative radiotherapy with electrons 
(ELIOT) trial demonstrated a significantly higher 5-year 
ipsilateral breast tumor recurrence compared to the WBEBRT 
arm (4.4% vs 0.4%, P=0.0001).96 Based on these data, IORT 
as definitive treatment is discouraged.
Current scenario
In view of higher rates of local recurrence with IORT and 
inadequate data to support its safety, efficacy, and wide-
spread adoption compared to WBEBRT or APBI, IORT is 
discouraged.
Discussion
Breast-conserving surgery with adjuvant RT is the standard 
treatment for ESNNBC. A recent meta-analysis found that in 
women with pN0 disease, RT reduced these risks from 31.0% 
to 15.6% (absolute recurrence reduction 15.4%, 13.2–17.6, 
2P<0.00001) and from 20.5% to 17.2% (absolute mortality 
reduction 3.3%, 0.8–5.8, 2P=0.005), respectively.100 With 
many long-term survivors, treatment-induced toxicities are 
a major consideration. Concerns regarding the necessity of 
whole breast irradiation, treatment-associated toxicities, qual-
ity of life (QOL) based on these treatments are the subjects 
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early stage breast cancer techniques
Data from population studies and older literature have 
shown increase in heart, lung, and LAD morbidity and mor-
tality.7,8,101 While pulmonary and cardiac toxicities affect the 
patients’ QOL, it is the cardiac toxicities that have a greater 
potential to become lethal. Hence, patients with left-sided 
breast cancer should be offered some form of heart dose 
sparing technique.
The literature search resulted in six RT techniques that 
have been consistently utilized and studied: 1) prone posi-
tioning, (2) PBT, (3) IMRT, (4) BH, (5) PBI, and (6) IORT 
(Table 1).
Of these techniques, PBT and PBI have consistently 
reduced OAR doses. The other techniques have demonstrated 
dose reduction to OARs in most cases, with some cases 
reporting an increase in OAR doses (Table 2).
APBI has consistently demonstrated great reductions in 
both high and low dose for the lungs, heart, and LAD. These 
reductions are possible as APBI only irradiates the lumpec-
tomy region compared to WBEBRT.20 When examining all 
APBI techniques, EB-APBI demonstrates many advantages 
over other techniques.102 First, EB-APBI is non-invasive. 
This potentially reduces the risk of invasive complications. 
Second, EB-APBI allows for widespread adoption as most 
centers are already performing 3D-CRT for other cancers. 
Third, adopting EB-APBI may be hassle-free compared 
to adopting brachytherapy APBI techniques as technical 
and quality assurance needs of external beam are much 
simpler. Fourth, treatment outcomes with EB-APBI may be 
more uniform across centers as the outcome is less opera-
tor dependent. Disadvantages of EB-APBI include errors 
contributed by breathing motions, treatment setup variation, 
and fractionation regime.
Fractionation regime for EB-APBI remains questionable. 
Multiple studies demonstrate different fractionation scheme 
and concerns regarding the steep aspect of the toxicity curve, 
thus cautions against its widespread adoption.91,103
However, the other APBI techniques which fall under the 
branch of brachytherapy can be safely delivered well within 
acceptable toxicity standards while achieving comparable 
OAR dose reduction. The premise of brachytherapy lies 
in the inverse square law inherent to radioactive sources 
which allows the delivery of high tumoricidal radiation dose 
within the tumor bed with substantial sparing of the normal 
surrounding tissues.104 Despite interstitial brachytherapy 
being a surgical procedure, it presents many advantages too. 
Reasons to decline standard adjuvant WBEBRT RT include 
traveling to radiation facilities, daily transport issues, old age, 
or physical handicap.105,106 Brachytherapy APBI may allow 
such patients to receive standard breast conserving treatment. 
Brachytherapy APBI, which can be completed over 4–5 days, 
potentially allows all localized therapy to be completed before 
the start of systemic therapy. This is crucial for local control 
as patients will need to undergo 4–6 months of chemotherapy 
prior to adjuvant breast RT. A disadvantage of brachytherapy 
APBI is the availability of brachytherapy APBI as a service 
in the radiation facility which the patient visits.
IORT is technically PBI. However, unlike other APBI 
techniques, radiation is delivered as a single fraction at the 
time of lumpectomy.107 This makes it an attractive alterna-
tive to standard WBEBRT or APBI. IORT is increasingly 
offered as definitive RT during breast conserving surgery. 
This is alarming as the pathological and nodal statuses are 
not reviewed prior to the administration of IORT. Further-
more with limited data supporting its safety and efficacy 
compared to other RT techniques, IORT is essentially an 
off-protocol treatment. Beyond clinical data, there exist 
significant concerns regarding the radiobiology and physics 
of IORT techniques. With respect to IORT utilizing 50 kv 
X-ray source, although the surface dose is 20 Gy, the dose is 
drastically attenuated to 5 Gy, as a single dose, at 1 cm from 
the source surface distance. This sharply contrasts against a 
typical APBI plan that delivers 3.4 Gy to the PTV. Hence, it 
is unsurprising that randomized trials report higher rates of 
local recurrence.108 Another significant concern is the lack of 
image guidance. Without it, identification and documentation 
of the precise location of dose delivery and dose received by 
OARs remain to be an estimation at best.
While IORT may appear promising, in view of poor 
clinical outcomes compared to standard WBEBRT, 
improper adherence to standard radiobiological principles 
in breast RT and a lack of proper standardized protocols 
for delivery, clinical data do not support the routine use 
of IORT.
Where APBI is unavailable or unsuitable, cardiac avoid-
ance techniques with WBEBRT should be explored. A differ-
ence in setup position can aid in OAR reduction.29 However, 
from the above data, it is found that OAR dose reduction is 
inconsistent with the prone position. Also, the prone posi-
tion requires special immobilization gadgets that may not be 
available in all centers.
IMRT is consistent in minimizing high dose to the heart, 
lungs, and LAD. However, the integral dose to these organs, 
the thorax and the contralateral breast, is often increased with 
uncertain clinical consequence. Another merit of IMRT is 
improved breast cosmesis.109 Patients who are well endowed 
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The rapid dose fall off beyond the Bragg peak of the 
proton beam allows for great reductions to OARs beyond 
the target volume. However, PBT is a significantly expen-
sive treatment and may not be economically attractive 
despite its consistent reduction in high and low dose to 
OARs (Table 2).
Patients who are suitable candidates for BH should be 
offered if available. BH like PBT consistently reduces high 
and low doses to heart. However, this is not consistently 
so for dose to the lungs. All BH delivery methods reduces 
dose to the heart. The dosimetric advantages with BH are 
encouraging. However, there remain two aspects of BH that 
needs further research.15 First, no clear selection criteria 
exist to identify which patient group will benefit most from 
BH other than the left-sided breast cancer patients. Cur-
rently, evidence suggests that parasagittal cardiac contact 
to the chest wall may be a suitable metric for BH selection. 
Second, the success of BH delivery is heavily dependent on 
patient’s compliance and treatment verification. These are 
additional areas that can be explored further together with 
coaching strategies.
The impairment of lung function is primarily dependent 
on the proportion of lung volume receiving a dose beyond 
its tolerance dose.110 Hence, although the lung is one of the 
most sensitive late responding organ, because of its functional 
units, only when large volumes of the lungs are irradiated 
does the lung become a dose-limiting organ.
Lung is inadvertently irradiated during breast RT. Although 
Lind et al had reassured that RP is an infrequent complication 
after local WBEBRT (0.9%), it is important to bear in mind 
that the incidence of RP increases with increase in age, con-
current tamoxifen, and prior chemotherapy.111 Smoking habits 
and pre-RT performance status are also important factors in 
determining the incidence and severity of RP.
Given the anatomical location of heart, potential cardio-
toxicity is associated with RT to the left breast. The incidence 
of ischemic heart disease has been correlated to the volume 
of heart irradiated and radiation dose received.5,6 Although 
these effects were dominant in early studies based on outdated 
RT techniques, they serve as a reminder to always minimize 
cardiac dose where possible. The dosimetric outcomes of 
clinical studies utilizing modern techniques suggest superior 
outcomes and a potential decrease in cardiac complications 
in future long-term follow-up studies. Clinical evidence sug-
gests that radiation to the heart has detrimental consequences 
despite latencies are estimated to become detectable at only 
>15 years after radiation treatment.112
The meta-analysis of the Early Breast Cancer Trialists’ Col-
laborative Group (EBCTCG) found that the gain in locoregional 
control did not fully translate to an improvement in overall 
survival.113 This was due to life-threatening side effects asso-
ciated with older RT regimens. The EBCTCG trial reported 
a significant excess (SE) incidence of contralateral breast 
cancer (rate ratio 1.18, SE 0.06, 2P=0.002) and a SE of non-
breast-cancer mortality in irradiated women (rate ratio 1.12, 
SE 0.04, 2P=0.001) at 15 years after breast RT. The mortality 
was attributed to cardiovascular disease (rate ratio 1.27, SE 
0.07, 2P=0.0001) and lung cancer as a secondary malignancy 
(rate ratio 1.78, SE 0.22, 2P=0.0004). This suggests that the 
survival benefit supposedly conferred with adjuvant breast RT 
was partially negated by the increase in cardiovascular-related 
death and lung cancer as a secondary malignancy. Therefore, 
this reinforces that reducing heart and lung irradiation should 
be a critical aspect in selecting the most appropriate radiation 
technique for the patient and radiation treatment planning. 
Patient factors like anatomy, tumor location, its anatomical 
relation to OAR, and breast contour should be borne in mind 
when deciding on the most appropriate RT technique.
Current data recommend that where possible and suitable, 
patients should be first offered PBI. The next best option for 
OAR dose reduction would be BH.
Long-term studies are needed to evaluate the effect of RT 
on the heart, LAD, and lungs with modern RT techniques in 
both the acute and late settings. This could also be particularly 
helpful in advising patients on lifestyle modification in cases 
of increased radiation-induced toxicity risks.
Conclusion
As RT techniques evolve, the focus on survival, control, 
recurrence, and tissue toxicities remains. Treatment options 
have to take into consideration patient’s schedule, QOL, and 
the financial impact of different techniques.
Currently, in terms of whole breast irradiation, dosimet-
ric data suggest that BH techniques allow for consistent car-
diac dose reduction at the expense of slight increase in lung 
doses. This is in contrast to techniques such as the prone 
position and IMRT. Although PBT achieves consistent OAR 
dose reduction too, the sheer significantly higher cost makes 
it unaffordable for most patients. In terms of PBI, APBI has 
comparable survival, control, and recurrence outcomes with 
even better cosmesis. IORT is cautioned against in view of 
its high failure rate and limited data. Among the various 
radiotherapy modalities, current evidence suggests that 
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